Trial reportClinical oral investigations2026
Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial.
Trial report in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlveolar ridge atrophy is an inevitable consequence following tooth extraction, leading to substantial vertical and horizontal bone loss and frequently complicating subsequent prosthetic rehabilitation. Simvastatin (SIM), known for its osteoinductive and anti-inflammatory properties, has shown promise in promoting local bone regeneration. This study aimed to evaluate the efficacy of topical application of a novel 1.2% SIM gel in preserving alveolar ridge dimensions following the surgical extraction of mandibular third molars, compared with a placebo.
methodsA randomized, triple-blind clinical trial (RCT) was conducted involving 40 patients (n = 20 per group) requiring mandibular third molar extraction. Patients were randomly assigned to receive either the active 1.2% SIM gel (test group) or a placebo gel (control group). In both groups, the assigned gel was delivered using a collagen sponge as a carrier scaffold placed directly into the extraction socket. Cone Beam Computed Tomography (CBCT) scans were obtained pre-extraction (T0) and 12 weeks postoperatively (T1). The primary outcome was the dimensional change in vertical alveolar bone height (ΔH). Secondary and exploratory outcomes included changes in bone width (ΔW), bone density (Mean Gray Value), postoperative pain, and swelling.
resultsThe primary outcome analysis included 38 sockets (n = 19 per group). The Test Group (SIM) showed significantly greater vertical bone preservation, with a mean change in height of − 0.30 ± 1.79 mm (indicating preservation/gain), compared to the Control Group’s mean loss of 1.28 ± 1.50 mm (p = 0.006). No statistically significant difference was observed in exploratory bone width preservation (p > 0.05). The SIM gel demonstrated an excellent safety profile, with no significant differences regarding postoperative pain or swelling compared to the placebo. CLINICAL SIGNIFICANCE: The topical application of 1.2% SIM gel significantly improved vertical alveolar bone height preservation at 12 weeks compared to the placebo. This primary finding confirms the clinical benefit of local simvastatin delivery in maintaining the vertical dimension required for successful prosthetic treatment, while exploratory densitometric data also suggested an improvement in coronal bone mineralization. This simple, low-cost pharmacological approach is highly effective in mitigating post-extraction vertical bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.